For a US perfume project, determine the actual MoCRA roles and applicable exemptions before assigning registration, listing, safety and label work. This guide distinguishes statutory dates, historical enforcement policy and the date sources were checked. Registration and listing are not FDA approval or a guarantee against delay.
Understanding MoCRA’s Impact on Perfume
MoCRA expanded FDA’s cosmetics framework. A body fragrance generally falls within cosmetics, but intended claims and use can affect classification. Review the actual product and entity rather than assuming every facility, small business or SKU has identical obligations.
Mandatory Facility Registration and Product Listing
Covered facility owners/operators and product responsible persons have different duties. Certain small-business and drug/device-related exemptions apply, and excluded product categories limit small-business relief. Record the actual eligibility analysis; exemption from one duty does not erase all cosmetic obligations.
- Facility registration: Covered owners/operators register the actual facility and renew every two years; required registration changes are updated within 60 days. FDA’s current page ties renewal to the initial registration date. Confirm exemptions and who submits for a contract facility.
- Product listing: The responsible person submits or ensures submission for covered marketed cosmetics and provides updates annually. Apply the current product/variant listing instructions; a commercial SKU count or every formula change does not automatically determine a new listing.
- Responsible person: The manufacturer, packer or distributor named on the product label under the statutory definition. Distinguish this from the foreign facility’s US agent.
- Initial deadlines: FDA guidance distinguishes facilities/products existing on 29 December 2022 from later starts. For later facilities, the statutory rule is within 60 days of first relevant activity or 27 February 2024, whichever later; later products use 120 days after first interstate marketing, with the guidance’s historical transition explained separately.
Action tip: Identify the actual manufacturing/processing facilities, obtain the appropriate FDA Establishment Identifier (FEI), map product/formula records and label-named responsible persons, and retain the registration/listing or exemption evidence. Do not use a DUNS number as a substitute for the FEI or request an FDA-issued cosmetic approval certificate.
Labeling Your Perfume: What’s New?
Existing FDA Labeling Rules
Apply current FDA cosmetic label requirements to the actual bottle/carton and claims. Review topics include:
- Identity statement: The product name or description (e.g., “Eau de Parfum”).
- Net contents: Use a volume declaration for liquid perfume; have the reviewer confirm the applicable metric/customary units, actual fill, rounding and package exceptions.
- Ingredients: Apply FDA’s naming/order rules and exceptions to the actual formula; fragrance declaration and allergen rule status need separate review.
- Distributor statement: Name and place of business of the manufacturer, packer, or distributor.
MoCRA Additions: Contact Information and Allergen Disclosure
Keep the adverse-event contact duty separate from fragrance-allergen rulemaking status:
1. Adverse-event contact: The statutory alternatives are a domestic address, domestic phone number or electronic contact information, which may include a website, through which the responsible person can receive reports. They are alternatives, not a universal address-plus-phone bundle. A functional electronic route does not automatically replace the separate business-name/address labeling rule.
2. Fragrance-allergen rulemaking: MoCRA directs FDA to establish disclosure requirements. The official agenda checked on 10 October 2026 shows proposed-rule stage with a projected November 2026 proposal. An agenda forecast is not an issued proposal, final rule or effective date. No US “over 80” proposed list is verified here; check the actual rulemaking before artwork approval.
Safety Substantiation: Proving Your Fragrance is Safe
Under MoCRA, a responsible person must ensure and maintain records showing adequate substantiation that a perfume is safe. This is not a new concept for responsible manufacturers, but now it is a legal requirement that FDA can inspect.
Have a qualified reviewer scope scientifically appropriate safety evidence for the actual product, use and claims. Possible data topics include:
- Controlled composition and relevant supplier information sufficient for qualified safety review, with confidential access arrangements.
- Qualified evaluation of the final formula, intended use, exposure and claims, using appropriate evidence.
- Formula/package-specific stability and microbiological evidence or justified approach under the technical safety plan; no universal test bundle.
Applicable supplier IFRA conformity information may support review but does not replace final-product safety substantiation. MoCRA does not impose the EU CPSR format or a universal named test panel. Set record-retention duties by record category and applicable law; the former blanket three-years-after-last-shipment statement is not established.
Responsibility and Evidence Matrix
| Workstream | Responsible role | Evidence to verify |
|---|---|---|
| Facility registration | Covered owner/operator; permitted contract-facility submitter arrangement | Actual site, FEI, submission/current status, renewal date or documented exemption |
| Product listing | Label-named responsible person | Product/formula identity, relevant facilities, submission and annual updates or exemption |
| Safety substantiation | Responsible person with qualified contributors | Actual product/use evidence and controlled records |
| Label/contact | Responsible person + qualified label reviewer | Final artwork, business identity and functioning report contact |
| Allergen rule tracking | Assigned regulatory reviewer | Actual publication, final status, applicability and effective/transition dates |
Keep three kinds of date separate
| Date type | Verified reference | How to use it |
|---|---|---|
| Statutory initial deadline | 29 December 2023 for facilities/products existing on 29 December 2022, subject to scope | Historical obligation, not today’s new-product launch date |
| Historical enforcement policy | FDA’s June 2024 update describes delayed enforcement until 1 July 2024 | Policy timing did not turn registration into approval or erase the statute |
| Current review date | 10 October 2026 | Check current facility status, actual renewal date, annual listing work and new rule publications |
FDA’s small-business definition uses average US cosmetic gross sales over the previous three years below $1 million adjusted for inflation, with specified product exclusions. Do not use the unadjusted figure as a current universal threshold or infer eligibility from order size. Obtain a documented entity/product assessment.
Sources checked on 10 October 2026: current FDA registration/listing page, December 2024 registration/listing guidance, historical enforcement-policy explanation, FDA MoCRA overview, label contact statute and allergen rulemaking agenda. FDA expressly states that registration/listing numbers are not approval and it does not issue compliance-verification certificates.
Frequently Asked Questions
Do I need to list each fragrance ingredient separately?
Apply current FDA ingredient declaration rules and the status of any relevant allergen rule. Do not substitute EU ingredient naming/counts for US requirements or assume fragrance grouping removes every other disclosure duty. Have the final formula and artwork reviewed.
My perfume is contract manufactured overseas. Who is responsible?
Identify the manufacturer, packer or distributor whose name appears on the label under the statutory definition. The responsible person is not required by that definition to be a US domestic entity. A foreign facility’s US agent is a separate facility-registration role; confirm both arrangements where applicable.
How soon must I report an adverse event?
FDA states that the responsible person reports serious adverse events within 15 business days, including the required label copy. Relevant additional information received within one year of the initial report has a further 15-business-day reporting requirement. Establish a qualified intake/escalation and record-retention procedure, including applicable small-business distinctions; do not apply one blanket retention period to every entity and record.
What if my label lacks the required contact?
Have the responsible person and label reviewer resolve the missing information before artwork release or further affected supply, as appropriate. A generic enforcement summary is not a product-specific legal determination.
Next Steps: Assign and Verify the Work
Assign named owners for facility work, listing, safety records, label review and adverse-event handling. Confirm the manufacturing supplier’s contracted support and any separate qualified regulatory or US-agent service.
To discuss the product brief and documentation scope, Request a Quote. Confirm responsibilities, current evidence and project milestones rather than assuming a guaranteed compliance service or launch date.